Patents by Inventor Robert A. Sikes

Robert A. Sikes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Utilization of osteocalcin promoter to deliver therapeutic genes to tumors
    Patent number: 6596534
    Abstract: A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: July 22, 2003
    Assignee: The University of Virginia Patent Foundation
    Inventors: Leland W. K. Chung, Chinghai Kao, Robert A. Sikes, Song-Chu Ko, Jun Cheon
  • Isolation and use of fetal urogenital sinus expressed sequences
    Publication number: 20020155119
    Abstract: The invention comprises methods for identifying biomarkers useful for prognostic or diagnostic assays of human prostate disease, and for identifying those fetal genes which are differentially expressed between prostate cancers versus normal or benign prostate.
    Type: Application
    Filed: August 22, 2001
    Publication date: October 24, 2002
    Inventors: Robert A. Sikes, Leland W.K. Chung, Jin Hee Kim, Claudia Fasciana, Jan Trapman
  • In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy
    Patent number: 6159467
    Abstract: A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: December 12, 2000
    Assignee: The University of Virginia Patent Foundation
    Inventors: Leland W. K. Chung, Chinghai Kao, Robert A. Sikes, Song-Chu Ko, Jun Cheon
  • Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
    Patent number: 5772993
    Abstract: A recombinant adenovirus Ad-OC-TK was constructed, with cell specific gene expression, which contains osteocalcin (OC) promoter that drives the expression of herpes simplex virus thymidine kinase (TK); the addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, to Ad-OC-TK resulted in the induction of osteoblast-specific cell death in vitro. The Ad-OC-TK virus plus ACV treatment is highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: June 30, 1998
    Assignee: The University of Virginia Patent Foundation
    Inventors: Leland W. K. Chung, Chinghai Kao, Robert A. Sikes, Song-Chu Ko, Jun Cheon